

Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, Dasheng Wang, Robert W. Brueggemeier, Charles L. Shapiro, and Ching-Shih Chen



This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.

Reference

1. Weng S-C, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, et al. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. *Mol Cancer Ther* 2008;7: 800-8.

Published online April 1, 2019.

doi: 10.1158/1535-7163.MCT-19-0151

©2019 American Association for Cancer Research.

Molecular Cancer Therapeutics

Retraction: Sensitizing Estrogen Receptor–negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor

Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp, et al.

Mol Cancer Ther 2019;18:869.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/4/869>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://mct.aacrjournals.org/content/18/4/869.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/4/869>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.